Trials / Completed
CompletedNCT01763307
A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI
A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic colorectal cancer patients. This study will prospectively accrue metastatic colorectal patients receiving EGFRI and treat with reconval cream half face versus placebo cream half face to study whether Vitamin k1 cream can prevent the typical skin eruption caused by EGFRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RECONVAL CREAM | |
| DRUG | PLACEBO |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-01-01
- Completion
- 2018-12-01
- First posted
- 2013-01-08
- Last updated
- 2024-02-29
Source: ClinicalTrials.gov record NCT01763307. Inclusion in this directory is not an endorsement.